Dr Jennifer Ngan Highlights the Results of the PARTNER Study at ATTD Asia 2025
We’d like to congratulate Dr Jennifer Ngan for her presentation at ATTD ASIA 2025. Dr Ngan’s presentation highlighted the early results of our ongoing PARTNER trial, which involved free living participants with type 1 diabetes wearing novel continuous ketone monitors (CKMs).
Continuous ketone monitors may identify transient ketosis missed by traditional intermittent finger prick measurement, allowing novel associations to be identified. We aimed to evaluate ketone profiles using continuous monitors in community dwelling adults with type 1 diabetes (T1D) and determine factors associated with increased ketone levels.
Demographic, dietary, HbA1c and continuous glucose monitor (CGM, Abbott Freestyle Libre 2) data, and 5-minutely ketone profiles were assessed using a CKM (Abbott) during two-weeks run-in for the PARTNER study (ACTRN12624000448549), with sodium-glucose cotransporter 2 (SGLT2) inhibitor use excluded.
The data of 53 participants was examined. Twenty-two recorded a ketone level of ≥0.6 mmol/L during the two weeks, with 14/53 (26%) between 0.6-0.9 mmol/L and 8/53 (15%) ≥1.0 mmol/L. Lower carbohydrate intake was associated with ketones ≥1.0 mmol/L (P=0.004). For every 10-year increase in diabetes duration, there was a 1.49 odds of baseline ketones ≥0.6 mmol/L (95% CI 1.02-2.26; P=0.049). There were no significant differences between groups according to age, sex, BMI, insulin delivery modality, average total daily insulin doses, HbA1c, eGFR and CGM metrics.
In conclusion, the majority of stable free-living T1D adults not on SGLT2 inhibitor had baseline ketone levels <0.6 mmol/L. Low daily carbohydrate intake and longer diabetes duration are associated with ketone levels ≥0.6 mmol/L.
To read more about the results of the PARTNER trial, follow this link to our previous post about the trial here and here
Dr Jennifer Ngan Highlights the Results of the PARTNER Study at ATTD Asia 2025
We’d like to congratulate Dr Jennifer Ngan for her presentation at ATTD ASIA 2025. Dr Ngan’s presentation highlighted the early results of our ongoing PARTNER trial, which involved free living participants with type 1 diabetes wearing novel continuous ketone monitors (CKMs).
Continuous ketone monitors may identify transient ketosis missed by traditional intermittent finger prick measurement, allowing novel associations to be identified. We aimed to evaluate ketone profiles using continuous monitors in community dwelling adults with type 1 diabetes (T1D) and determine factors associated with increased ketone levels.
Demographic, dietary, HbA1c and continuous glucose monitor (CGM, Abbott Freestyle Libre 2) data, and 5-minutely ketone profiles were assessed using a CKM (Abbott) during two-weeks run-in for the PARTNER study (ACTRN12624000448549), with sodium-glucose cotransporter 2 (SGLT2) inhibitor use excluded.
The data of 53 participants was examined. Twenty-two recorded a ketone level of ≥0.6 mmol/L during the two weeks, with 14/53 (26%) between 0.6-0.9 mmol/L and 8/53 (15%) ≥1.0 mmol/L. Lower carbohydrate intake was associated with ketones ≥1.0 mmol/L (P=0.004). For every 10-year increase in diabetes duration, there was a 1.49 odds of baseline ketones ≥0.6 mmol/L (95% CI 1.02-2.26; P=0.049). There were no significant differences between groups according to age, sex, BMI, insulin delivery modality, average total daily insulin doses, HbA1c, eGFR and CGM metrics.
In conclusion, the majority of stable free-living T1D adults not on SGLT2 inhibitor had baseline ketone levels <0.6 mmol/L. Low daily carbohydrate intake and longer diabetes duration are associated with ketone levels ≥0.6 mmol/L.
To read more about the results of the PARTNER trial, follow this link to our previous post about the trial here and here